For the patients, the appearance of
the inhaled drug therapy has been a significant advantage with the respiratory
disorders such as COPD and the asthma due to its painless and flexible
administration when equated to the injections. There are several types of the
inhalation systems obtainable in the market, and these involve inhalers and
nebulizers. The two greatest frequent prevalent respiratory disorders are the
asthma and COPD.
According to the report analysis, ‘US
Inhalation Systems Market Forecast up to 2024’ states that there are
several key players which are presently functioning in this sector more
actively for dominating the highest value of market share and leading the
fastest market growth in the short span of time while increasing the prevalence
of the respiratory diseases, effective advancements in the technology and
decreased in the side effects allied with the drug inhalation includes Omron
Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex
Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca
PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan
Medical Corporation, GlaxoSmithKline plc, Becton Dickinson.
According to the WHO, approximately
235 million people are presently suffering from the asthma, and it is very much
general in the children. The Chronic respiratory disease such as asthma and
COPD are accountable for the considerable financial and health burden in the
US, and in 2015, 6.7% death in the US were owing to the chronic respiratory
disorders. Moreover, chronic obstructive pulmonary disease is the third
important reason of death around the globe, in 2016 accounting for
approximately 3 million deaths. State of West Virginia has the uppermost
pervasiveness of COPD, and nearby 12% of the populace are detected with COPD.
However, in the present years, there
is an augment in the approvals owing to the acceptance of the systems and also
the drug companies are introducing the new inhalation systems and cooperating
with the other vendors to enhance the innovative devices in the market. For
instance, in February 2017, FDA permitted two products advanced by Teva Pharmaceutical
Industries Ltd., ArmonAir RespiClick and AirDuo RespiClick, to delight the
adolescent and adult patients with asthma.
Additionally, the US Inhalation
Systems Market is predicted to witness an effective CAGR of 5.8% during the
forecast period of 2018-2024. Whereas, the market of inhalation systems in US
is segmented into different sectors which majorly involves products,
applications and end-users. Whereas, based on the end user, the market is
further divided into hospitals, ambulatory care centers, and home care centers.
For instance, the hospitals attained a major market share in 2017, and home
care sector is predicted to increase during the forecast period owing to the
ease in the utilization of modern products, less homecare cost, and the accessibility
of reimbursement.
Although, the US inhalation systems
market is fueled by an upsurge in the prevalence of respiratory diseases,
augmenting the geriatric population, and favorable reimbursement. Therefore, in
the coming years, it is predicted that the market of inhalation systems in US
will increase more positively over the recent few years.
To know more, click on the link
below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249
